In this issue of Clinics in Liver Disease, guest editor Dr. Zobair M. Younossi brings his considerable expertise to the topic of MASH/NASH Fatty Liver. With an estimated 115 million people worldwide affected by MASH, the disease burden casts a wide net: many have other comorbidities, like diabetes, that make diagnosis and treatment critical. MASH-related liver cancer has increased 20% since 1990, and MASH is becoming a leading cause of liver transplants in adults, reflecting its significant impact on liver health. This issue provides state-of-the-art clinical reviews on MASH and NASH and also shines a light on the disease burden across the globe.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xvii 7. Preface - p. xix 8. Metabolic Dysfunction-Associated Steatotic Liver Disease: Global Epidemiology, Patient-Reported Outcomes, and Economic Impact - p. 241 9. Association of Metabolic Dysfunction-Associated Steatohepatitis with Metabolic-Related Diseases: Diabetes, Prediabetes, and Obesity - p. 271 10. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease with Extrahepatic Cancers and Sarcopenia - p. 289 11. Metabolic Liver Disease Beyond the Liver: Association of Metabolic Dysfunction-Associated Steatotic Liver Disease with Cardiovascular and Renal Diseases - p. 301 12. Noninvasive Testing for Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis - p. 323 13. Algorithms for Risk Stratification in Patients with Metabolic Dysfunction-Associated Steatohepatitis - p. 343 14. Management of Metabolic Dysfunction-Associated Steatotic Liver Disease with Lifestyle Modification - p. 359 15. Treatment of Modifiable Risks in Metabolic Dysfunction-Associated Steatotic Liver Disease: Drugs Targeting Obesity and Type 2 Diabetes - p. 381 16. Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis - p. 391 17. Special Populations: Hepatocellular Carcinoma Risk and Liver Transplantation - p. 417 18. Special Population: Lean MASH - p. 435 19. Special Population: A Global Perspective on Metabolic Dysfunction-Associated Alcohol-Related Liver Disease - p. 449 20. What’s New in Pediatric Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis - p. 470 21. Metabolic Dysfunction-Associated Steatohepatitis in the Middle East: Clinical Challenges and Strategies to Bridge the Gap - p. 483 22. Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management - p. 495 23. Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa: From Burden to Action - p. 513 24. Metabolic Dysfunction-Associated Steatotic Liver Disease in Latin America - p. 529 25. Metabolic Dysfunction Associated Steatohepatitis (MASH) in Oceania, Central America, and the Caribbean - p. 543 26. Metabolic Dysfunction-Associated Steatotic Liver Disease and Viral Hepatitis - p. 557
In this issue of Clinics in Liver Disease, guest editor Dr. Zobair M. Younossi brings his considerable expertise to the topic of MASH/NASH Fatty Liver. With an estimated 115 million people worldwide affected by MASH, the disease burden casts a wide net: many have other comorbidities, like diabetes, that make diagnosis and treatment critical. MASH-related liver cancer has increased 20% since 1990, and MASH is becoming a leading cause of liver transplants in adults, reflecting its significant impact on liver health. This issue provides state-of-the-art clinical reviews on MASH and NASH and also shines a light on the disease burden across the globe.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xvii 7. Preface - p. xix 8. Metabolic Dysfunction-Associated Steatotic Liver Disease: Global Epidemiology, Patient-Reported Outcomes, and Economic Impact - p. 241 9. Association of Metabolic Dysfunction-Associated Steatohepatitis with Metabolic-Related Diseases: Diabetes, Prediabetes, and Obesity - p. 271 10. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease with Extrahepatic Cancers and Sarcopenia - p. 289 11. Metabolic Liver Disease Beyond the Liver: Association of Metabolic Dysfunction-Associated Steatotic Liver Disease with Cardiovascular and Renal Diseases - p. 301 12. Noninvasive Testing for Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis - p. 323 13. Algorithms for Risk Stratification in Patients with Metabolic Dysfunction-Associated Steatohepatitis - p. 343 14. Management of Metabolic Dysfunction-Associated Steatotic Liver Disease with Lifestyle Modification - p. 359 15. Treatment of Modifiable Risks in Metabolic Dysfunction-Associated Steatotic Liver Disease: Drugs Targeting Obesity and Type 2 Diabetes - p. 381 16. Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis - p. 391 17. Special Populations: Hepatocellular Carcinoma Risk and Liver Transplantation - p. 417 18. Special Population: Lean MASH - p. 435 19. Special Population: A Global Perspective on Metabolic Dysfunction-Associated Alcohol-Related Liver Disease - p. 449 20. What’s New in Pediatric Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis - p. 470 21. Metabolic Dysfunction-Associated Steatohepatitis in the Middle East: Clinical Challenges and Strategies to Bridge the Gap - p. 483 22. Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management - p. 495 23. Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa: From Burden to Action - p. 513 24. Metabolic Dysfunction-Associated Steatotic Liver Disease in Latin America - p. 529 25. Metabolic Dysfunction Associated Steatohepatitis (MASH) in Oceania, Central America, and the Caribbean - p. 543 26. Metabolic Dysfunction-Associated Steatotic Liver Disease and Viral Hepatitis - p. 557
